Yuchao Jin, PA
Medical · San Diego, CANPI 1518454396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 1,049 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $7,355, 2.6 times the $2,820 reported in 2021. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$4K
- UCB, Inc.$2K
- Johnson & Johnson$2K
- Novartis$1K
- GSK$1K
- plus $7K from 32 others
What the payments were for
- Food & beverage$21,846100%
- Education$670%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 227 | $4,372 |
| AbbVie | 234 | $4,323 |
| UCB, Inc. | 103 | $2,211 |
| Johnson & Johnson | 82 | $2,035 |
| Novartis | 70 | $1,231 |
| GSK | 57 | $1,191 |
| Lilly USA, LLC | 36 | $924 |
| AstraZeneca(2 entities) | 48 | $923 |
| Mallinckrodt Hospital Products Inc. | 30 | $888 |
| Aurinia Pharma U.S., Inc. | 37 | $826 |
| Boehringer Ingelheim | 15 | $518 |
| Radius Health, Inc. | 16 | $312 |
| Pfizer | 18 | $293 |
| ANI Pharmaceuticals, Inc. | 11 | $252 |
| Sanofi | 7 | $182 |
| Kyowa Kirin, Inc. | 4 | $177 |
| Scilex Pharmaceuticals Inc. | 7 | $159 |
| Genentech USA, Inc. | 6 | $134 |
| Janssen Scientific Affairs, LLC | 1 | $117 |
| Actelion Pharmaceuticals US, Inc. | 7 | $116 |
| Alnylam Pharmaceuticals Inc. | 4 | $109 |
| Antares Pharma, Inc. | 6 | $87 |
| Biocryst US Sales Co., LLC | 2 | $73 |
| Sandoz | 4 | $71 |
| Cumberland Pharmaceuticals, Inc. | 2 | $58 |
| E.r. Squibb & Sons, L.L.C. | 1 | $42 |
| Novo Nordisk | 2 | $40 |
| Celltrion USA Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $31 |
| Biogen | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| Echosens North America, Inc. | 1 | $22 |
| Tonix Medicines, Inc. | 1 | $21 |
| CSL Behring | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,914 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 33 | $453,286 |
| Enbrel SureclickEtanercept | 20 | $206,290 |
| RinvoqUpadacitinib | 30 | $186,853 |
| Xeljanz XrTofacitinib Citrate | 19 | $117,111 |
| Hadlima(Cf) PushtouchAdalimumab-Bwwd | 11 | $16,980 |
| Hydroxychloroquine Sulfate | 160 | $9,219 |
| MethotrexateMethotrexate Sodium | 153 | $4,247 |
| Pregabalin | 20 | $2,332 |
| Celecoxib | 53 | $2,160 |
| Leflunomide | 28 | $1,328 |
| Duloxetine Hcl | 46 | $1,053 |
| Leucovorin Calcium | 17 | $1,050 |
| Azathioprine | 20 | $984 |
| Sulfasalazine | 20 | $804 |
| Mycophenolate Mofetil | 15 | $435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,323 | $186,85330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in San Diego
- Cheryl KyinnSan Diego$103K
- Touraj YariSan Diego$27K
- Aaron WillcottSan Diego$23K
- Carter CopelandSan Diego$17K
- Cameron ChanSan Diego$16K
- Melanie GloverSan Diego$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.